Human PD-L2/B7-DC PicoKine ELISA Kit
To Order Contact us: [email protected]
Recombinant Human B7-DC/PD-L2/CD273 Protein |
|||
RP00150 | Abclonal | 20 μg | EUR 231.6 |
Recombinant Human B7-DC/PD-L2/CD273 Protein |
|||
RP00988 | Abclonal | 10 μg | EUR 186 |
Human CellExp? PD-L2 / B7-DC, mouse recombinant |
|||
P1087-10 | Biovision | each | EUR 170.4 |
Human CellExp? PD-L2 / B7-DC, mouse recombinant |
|||
P1087-50 | Biovision | each | EUR 548.4 |
Human CellExp? CD273 / B7-DC / PD-L2, human recombinant |
|||
7369-10 | Biovision | each | EUR 294 |
Human CellExp? CD273 / B7-DC / PD-L2, human recombinant |
|||
7369-50 | Biovision | each | EUR 836.4 |
Recombinant Mouse PD-L2/B7-DC/CD273 Protein |
|||
RP00660 | Abclonal | 10 μg | EUR 174 |
Recombinant Human PD-L2/B7-DC/CD273 (C-mFC) |
|||
CW20-10ug | Novoprotein | 10ug | EUR 175.2 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Human PD-L2/B7-DC/CD273 (C-mFC) |
|||
CW20-1mg | Novoprotein | 1mg | EUR 2739.6 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Human PD-L2/B7-DC/CD273 (C-mFC) |
|||
CW20-500ug | Novoprotein | 500ug | EUR 1935.6 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Human PD-L2/B7-DC/CD273 (C-mFC) |
|||
CW20-50ug | Novoprotein | 50ug | EUR 363.6 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Human PD-L2/B7-DC/CD273 (C-6His) |
|||
CA09-10ug | Novoprotein | 10ug | EUR 242.4 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl,pH7.4. |
Recombinant Human PD-L2/B7-DC/CD273 (C-6His) |
|||
CA09-1mg | Novoprotein | 1mg | EUR 2739.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl,pH7.4. |
Recombinant Human PD-L2/B7-DC/CD273 (C-6His) |
|||
CA09-500ug | Novoprotein | 500ug | EUR 1935.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl,pH7.4. |
Recombinant Human PD-L2/B7-DC/CD273 (C-6His) |
|||
CA09-50ug | Novoprotein | 50ug | EUR 595.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl,pH7.4. |
Recombinant Mouse PD-L2/B7-DC/CD273 (C-Fc) |
|||
CJ99-10ug | Novoprotein | 10ug | EUR 120 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L2/B7-DC/CD273 (C-Fc) |
|||
CJ99-1mg | Novoprotein | 1mg | EUR 814.8 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L2/B7-DC/CD273 (C-Fc) |
|||
CJ99-500ug | Novoprotein | 500ug | EUR 589.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L2/B7-DC/CD273 (C-Fc) |
|||
CJ99-50ug | Novoprotein | 50ug | EUR 230.4 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Rat Anti-Mouse PD-L2 (B7-DC) Monoclonal antibody, clone TY25 |
|||
CABT-L4293-1mg | Creative Diagnostics | 1 mg | EUR 1076.4 |
Rat Anti-Mouse PD-L2 (B7-DC) Monoclonal antibody, clone TY25 |
|||
CABT-L4293-5mg | Creative Diagnostics | 5 mg | EUR 2886 |
Human PD-L1/B7-H1 PicoKine ELISA Kit |
|||
EK1449 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of human PD-L1 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA). |
Mouse PD-L1/B7-H1 PicoKine ELISA Kit |
|||
EK1450 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of mouse PD-L1 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA). |
anti-B7 DC |
|||
YF-PA21096 | Abfrontier | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal to B7 DC |
Human PD-1 PicoKine ELISA Kit |
|||
EK0959 | BosterBio | 96 wells | EUR 546 |
Description: For quantitative detection of human PD-1 in cell culture supernates, serum and plasma(heparin). |
PD-L2 Antibody |
|||
4063-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1. |
PD-L2 Antibody |
|||
4063-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1. |
PD-L2 Peptide |
|||
4063P | ProSci | 0.05 mg | EUR 197.7 |
Description: (IN) PD-L2 peptide |
PD-1:PD-L2 Homogeneous Assay Kit |
|||
72015 | BPS Bioscience | 384 rxns. | EUR 1070 |
Description: The PD-1:PD-L2 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L2. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L2 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts. |
Human B7-1/CD80 PicoKine ELISA Kit |
|||
EK0707 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of human CD80 in cell culture supernates and serum. |
Polyclonal Anti-B7-DC antibody |
|||
APR05481G | Leading Biology | 0.1ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Anti-B7-DC . This antibody is tested and proven to work in the following applications: |
Anti-B7 DC/PDCD1LG2 Antibody |
|||
PB10010 | BosterBio | 100ug/vial | EUR 352.8 |
PD-1:PD-L2 TR-FRET Assay Kit |
|||
72012 | BPS Bioscience | 384 rxns. | EUR 1070 |
Description: The PD-1:PD-L2 TR-FRET Assay Kit is designed to measure the inhibition of PD-1 binding to_x000D_PD-L2 in a homogeneous 384 reaction format. Cell signaling through the PD-1 receptor upon_x000D_binding the PD-L2 ligand attenuates immune responses and is exploited by both tumors and_x000D_viruses. This FRET-based assay requires no time-consuming washing steps, making it_x000D_especially suitable for high throughput screening applications. The assay procedure is_x000D_straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled_x000D_acceptor, biotin-labeled PD-L2, and an inhibitor is incubated for two hours. Then, the_x000D_fluorescence intensity is measured using a fluorescence reader. |
PD-L2 Polyclonal Antibody |
|||
ES8685-100ul | ELK Biotech | 100ul | EUR 334.8 |
Description: A Rabbit Polyclonal antibody against PD-L2 from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
PD-L2 Polyclonal Antibody |
|||
ES8685-50ul | ELK Biotech | 50ul | EUR 248.4 |
Description: A Rabbit Polyclonal antibody against PD-L2 from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
PD-L2 Recombinant Protein |
|||
91-721 | ProSci | 0.05 mg | EUR 821.4 |
Description: Programmed Cell Death 1 Ligand 2 (PDCD1LG2) is a member of the BTN/MOG family. PDCD1LG2 contains one Ig-like C2-type domain and one Ig-like V-type domain. PDCD1LG2 is highly expressed in the heart, placenta, pancreas, lung and liver; it is weakly expressed in the spleen, lymph nodes, and thymus. PDCD1LG2 is involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PDCD1LG2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production. |
PD-L2 Recombinant Protein |
|||
92-497 | ProSci | 0.05 mg | EUR 437.1 |
Description: Programmed cell death 1 ligand 2 (PD-L2), also known as butyrophilin B7-DC or PDCD1 ligand 2, belongs to the member of B7 family which can regulate the activation and tolerance of T cells. PD-L2 is one ligand for Programmed cell death 1(PD-1), and the other is PD-L1. These two ligands shares 34% aa sequence identity. Mouse PD-L2 gene encodes a 273 amino acids (aa) protein with a putative 19 aa signal peptide, a 201 aa extracellular region , a 21 aa transmembrane domain and a 32 aa cytoplasmic region. The mouse PD-L2 gene is highly expressed in heart, placenta, pancreas, lung and liver while expressed weakly in spleen, lymph nodes and thymus. Besides, the expression of PD-L2 gene can be induced on dendritic cells grown from peripheral blood mononuclear cells under CSF2 and IL4/interleukin-4 treatment, and up-regulated by IFNG/IFN-gamma stimulation in monocytes. PD-L2 usually functions in a PDCD1-independent manner and is involved in regulating costimulatory signal which is essential for T-cell proliferation and IFNG production. Recent studies demonstrate that the expression of PD-L2 on the tumor cells promotes CD8 T cell–mediated rejection of tumor cells, at both the induction and effector phase of antitumor immunity. Moreover, PD-L2 binds to PD-1 cells and enhances T cell killing in a PD-1–independent mechanism. |
PD-L2 Polyclonal Antibody |
|||
ABP59870-003ml | Abbkine | 0.03ml | EUR 189.6 |
Description: A polyclonal antibody for detection of PD-L2 from Human. This PD-L2 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human PD-L2 protein at amino acid sequence of 31-80 |
PD-L2 Polyclonal Antibody |
|||
ABP59870-01ml | Abbkine | 0.1ml | EUR 346.8 |
Description: A polyclonal antibody for detection of PD-L2 from Human. This PD-L2 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human PD-L2 protein at amino acid sequence of 31-80 |
PD-L2 Polyclonal Antibody |
|||
ABP59870-02ml | Abbkine | 0.2ml | EUR 496.8 |
Description: A polyclonal antibody for detection of PD-L2 from Human. This PD-L2 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human PD-L2 protein at amino acid sequence of 31-80 |
PD-L2 Recombinant Protein |
|||
96-938 | ProSci | 0.1 mg | EUR 651.3 |
Description: Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production. |
PD-L2 Recombinant Protein |
|||
97-021 | ProSci | 0.1 mg | EUR 651.3 |
Description: Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production. |
PD-L2 Recombinant Protein |
|||
97-022 | ProSci | 0.1 mg | EUR 651.3 |
Description: Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production. |
Anti-PD-L2 antibody |
|||
STJ98748 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to PD-L2. |
ELISA kit for Human PD-L1/B7-H1 |
|||
EK5678 | SAB | 96 tests | EUR 663.6 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Human PD-L1/B7-H1 in samples from serum, plasma, tissue homogenates and other biological fluids. |
QuickDetect? PD-L1/B7-H1 (Human) ELISA Kit |
|||
K4416-100 | Biovision | each | EUR 1096.8 |
B7-H1/PD-L1 |
|||
E21-315 | EnoGene | 10ug | EUR 411.6 |
Mouse B7-1/CD80 PicoKine ELISA Kit |
|||
EK0708 | BosterBio | 96 wells | EUR 547.2 |
Description: For quantitative detection of mouse CD80 in cell culture supernates and serum. |
Rat CD80/B7-1 PicoKine ELISA Kit |
|||
EK0709 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of rat CD80 in cell culture supernates and serum. |
Mouse CD86/B7-2 PicoKine ELISA Kit |
|||
EK0711 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of mouse CD86 in cell culture supernates and serum. |
Rat CD86/B7-2 PicoKine ELISA Kit |
|||
EK0712 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of rat CD86 in cell culture supernates and serum. |
PD-1:PD-L2[Biotinylated] Inhibitor Screening Assay Kit |
|||
72004 | BPS Bioscience | 96 rxns. | EUR 1095 |
Description: The PD-1:PD-L2[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-L2 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-1 is coated on a 96-well plate. Next, PD-L2 is incubated with PD-1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader. |
PD-1[Biotinylated]:PD-L2 Inhibitor Screening Assay Kit |
|||
72006 | BPS Bioscience | 96 rxns. | EUR 1235 |
Description: The PD-L2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L2 is coated on a 96-well plate. Next, PD-1 is incubated with PD-L2 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader. |
PD-L2 (CD273), Fc fusion (Human) |
|||
71107 | BPS Bioscience | 100 µg | EUR 330 |
Description: Human secreted Programmed Death Ligand 2 (PD-L2)-Fc fusion protein, also known as CD273, PDCDL1G2, and B7-DC, GenBank Accession No. NM_025239, a.a. 20-219, fused at the C-terminus to the Fc portion of human IgG1 expressed in a HEK293 cell expression system. MW = 49 kDa. |
PD-1:PD-L1/PD-L2 Cell-Based Inhibitor Screening Assay Kit |
|||
60800 | BPS Bioscience | 96 rxns. | EUR 1070 |
Description: The PD-1/PD-L1 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of PD-1:PD-L1 or PD-1:PD-L2 interaction. The assay consists of two main components:_x000D_ • PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing human PD-1. These cryopreserved cells are provided in a thaw-and-use format that does not require cell propagation._x000D_ • _x000D_Expression vectors for TCR activator, human PD-L1, and human PD-L2: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L1 or PD-L2 and an engineered cell surface T cell receptor (TCR) activator._x000D_ |
Human B7-1/CD80 PicoKine™ Fast ELISA Kit |
|||
FEK0707 | BosterBio | 96 wells | EUR 570 |
Description: The Fast version of Picokine ELISA kits, assay takes less than 1.5 hours. Detect Human B7-1/CD80 with <10pg/ml sensitivity. Format: 96-well plate with removable strips. Compatible samples: cell culture supernates and serum. This is a TMB colorimetric sandwich ELISA kit with short assay time and fast experiment set up. B7-1/CD80 tissue specificity: Expressed on activated B-cells, macrophages and dendritic cells. |
CD273 [PD-L2] Recombinant Protein |
|||
90-425 | ProSci | 100 ug | EUR 651.3 |
Description: T cells require a signal induced by the engagement of the T cell receptor and a costimulatory signal(s) through distinct T cell surface molecules for optimal T cell activation and tolerance. CD273 (PD-L2) is one of two ligands for programmed death-1 (PD-1; CD279), a member of the CD28 family of immunoreceptors. The other identified ligand is PD-L1. CD273 is broadly expressed and also up regulated in a variety of tumor cell lines. On previously activated T cells, CD273 interaction with PD-1 inhibits TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. CD273 has a costimulatory function on resting T cells activated with suboptimal TCR signals. |
CD273 [PD-L2] Recombinant Protein |
|||
90-427 | ProSci | 100 ug | EUR 651.3 |
Description: T cells require a signal induced by the engagement of the T cell receptor and a costimulatory signal(s) through distinct T cell surface molecules for optimal T cell activation and tolerance. CD273 (PD-L2) is one of two ligands for programmed death-1 (PD-1; CD279), a member of the CD28 family of immunoreceptors. The other identified ligand is PD-L1. CD273 is broadly expressed and also up regulated in a variety of tumor cell lines. On previously activated T cells, CD273 interaction with PD-1 inhibits TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. CD273 has a costimulatory function on resting T cells activated with suboptimal TCR signals. |
CD273 [PD-L2] Recombinant Protein |
|||
90-428 | ProSci | 100 ug | EUR 651.3 |
Description: T cells require a signal induced by the engagement of the T cell receptor and a costimulatory signal(s) through distinct T cell surface molecules for optimal T cell activation and tolerance. CD273 (PD-L2) is one of two ligands for programmed death-1 (PD-1; CD279), a member of the CD28 family of immunoreceptors. The other identified ligand is PD-L1. CD273 is broadly expressed and also up regulated in a variety of tumor cell lines. On previously activated T cells, CD273 interaction with PD-1 inhibits TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. CD273 has a costimulatory function on resting T cells activated with suboptimal TCR signals. |
ELISA kit for Mouse PD-L1/B7-H1 |
|||
EK5679 | SAB | 96 tests | EUR 663.6 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse PD-L1/B7-H1 in samples from serum, plasma, tissue homogenates and other biological fluids. |
Ribosome-inactivating protein PD-L1/PD-L2 Antibody |
|||
1-CSB-PA306294LA01PJJ | Cusabio |
|
|
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA |
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody |
|||
20-abx319445 | Abbexa |
|
|
PD-L1/B7-H1/CD274 |
|||
E21-J88 | EnoGene | 10ug | EUR 411.6 |
PD-1:PD-L2[Biotinylated] Inhibitor Screening Colorimetric Assay Kit |
|||
72017 | BPS Bioscience | 96 rxns. | EUR 1095 |
Description: Cell signaling through the PD-1 receptor upon binding the PD-L2 ligand_x000D_attenuates immune responses and is exploited by both tumors and viruses. The PD-1:PDL2[_x000D_Biotinylated] Inhibitor Screening Colorimetric Assay Kit is designed for screening inhibitors of_x000D_PD-L2 ligand binding to PD-1 receptor. The key to this kit is the high affinity of biotin-labeled PD-L2 for streptavidin-HRP._x000D_Only a few simple steps on a microtiter plate are required for the assay. First, PD-1 is coated on_x000D_a 96-well plate. Next, PD-L2 is incubated with PD-1 on the plate. Finally, the plate is treated with_x000D_streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which_x000D_can then be measured using a UV/Vis spectrophotometer microplate reader. |
PD-1[Biotinylated]:PD-L2 Inhibitor Screening Colorimetric Assay Kit |
|||
72019 | BPS Bioscience | 96 rxns. | EUR 1095 |
Description: Cell signaling through the PD-1 receptor upon binding the PD-L2 ligand_x000D_attenuates immune responses and is exploited by both tumors and viruses. The PD-_x000D_1[Biotinylated]:PD-L2 Inhibitor Screening Colorimetric Assay Kit is designed for screening_x000D_inhibitors of PD-1 receptor binding to PD-L2 ligand. The key to this kit is the high affinity of biotin-labeled PD-1 for_x000D_streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First,_x000D_PD-L2 is coated on a 96-well plate. Next, PD-1 is incubated with PD-L2 on the plate. Finally, the_x000D_plate is treated with streptavidin-HRP followed by addition of a colorimetric HRP substrate_x000D_substrate to produce color, which can then be measured using a UV/Vis spectrophotometer_x000D_microplate reader. |
PD-1:PD-L2 Cell-Based Inhibitor Screening Assay Kit |
|||
79378 | BPS Bioscience | 96 rxns. | EUR 615 |
Description: The PD-1/PD-L2 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of the PD-1:PD-L2 interaction. The assay consists of two main components:_x000D_• Growth-Arrested PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing Human PD-1. These cryopreserved cells are provided in a thaw-anduse format that does not require cell propagation. These cells are modified not to be expanded and are intended to be used in a single experiment._x000D_• Expression vectors for TCR activator and Human PD-L2: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L2 and an engineered cell surface T cell receptor (TCR) activator. |
PD-L2 / TCR Activator Mammalian Expression Kit |
|||
60620 | BPS Bioscience | 500 rxns. | EUR 565 |
Description: The recombinant expression vectors are designed to express human engineered T cell receptor (TCR) activator and human PD-L2 (GenBank Accession #NM_025239) in mammalian cells. The transfected cells can be used in conjunction with PD-1/NFAT Reporter/Jurkat T cells (BPS #60535) to study the interactions of PD-1 with PD-L2 ligand in a cellular context and screen for modulators of this signaling pathway._x000D_In this assay, PD-1/NFAT Reporter/Jurkat T cells are used as effector cells; HEK293 cells overexpressing PD-L1 (or PD-L2) and an engineered T cell receptor (TCR) activator are used as target cells. When these two cells are co-cultivated, TCR complexes on effector cells are activated by TCR activator on target cells, resulting in expression of the NFAT luciferase reporter. However, PD1 and PD-L1 or PD-L2 ligation prevents TCR activation and suppresses the NFAT-responsive luciferase activity. This inhibition can be specifically reversed by anti-PD1 or anti-PD-L1 antibodies. PD1, PD-L1, or PD-L2 neutralizing antibodies block PD1:PD-L1 and/or PD1:PD-L2 interaction and promote T cell activation, resulting in reactivation of the NFAT responsive luciferase reporter. |
Mouse Anti-Human CD273 (PD-L2) mAb |
|||
CM031-100ug | SAB | 100ug | EUR 250.8 |
Mouse Anti-Human CD273 (PD-L2) mAb |
|||
CM031-25ug | SAB | 25ug | EUR 154.8 |
PD-L2, Fc Chimera (HEK293-expressed), Human |
|||
HY-P7399 | MedChemExpress | 50ug | EUR 321.6 |
TranslationBlocker Human PD-L2/ CD273 siRNA, 10nmol |
|||
QX8-10nmol | EnQuireBio | 10nmol | EUR 452.4 |
TranslationBlocker Human PD-L2/ CD273 siRNA, 2nmol |
|||
QX8-2nmol | EnQuireBio | 2nmol | EUR 331.2 |
Phytolacca dioica Ribosome-inactivating protein PD-L1/PD-L2 |
|||
1-CSB-EP306294PJJ | Cusabio |
|
|
Description: Recombinant Phytolacca dioica Ribosome-inactivating protein PD-L1/PD-L2 expressed in E.coli |
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (HRP) |
|||
20-abx319446 | Abbexa |
|
|
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (FITC) |
|||
20-abx319447 | Abbexa |
|
|
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (Biotin) |
|||
20-abx319448 | Abbexa |
|
|
Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody |
|||
A64216-020 | EpiGentek | 20 ul | EUR 117.7 |
Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody |
|||
A64216-050 | EpiGentek | 50 ul | EUR 302.5 |
Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody |
|||
A64216-100 | EpiGentek | 100 ul | EUR 423.5 |
Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody |
|||
A64216 | EpiGentek |
|
|
Recombinant Human PD-L1/B7-H1 Protein |
|||
RP00068 | Abclonal | 5 μg | EUR 163.2 |
Recombinant Human PD-L1/B7-H1 Protein |
|||
RP00184 | Abclonal | 10 μg | EUR 178.8 |
PD-L1 / B7-H1 Recombinant Protein |
|||
11-345 | ProSci | 0.1 mg | EUR 714.3 |
Description: Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
F55054-0.1ML | NSJ Bioreagents | 0.1ml | EUR 399 |
PD-L1 Antibody / B7-H1 / CD274 |
|||
R32479 | NSJ Bioreagents | 100 ug | EUR 419 |
PD-L1 Antibody / B7-H1 / CD274 |
|||
R32579 | NSJ Bioreagents | 100 ug | EUR 419 |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7823-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7823-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7823SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7974-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7974-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7974SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7988-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7988-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7988SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8009-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8009-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8009SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8067-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8067-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8067SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955BTN | NSJ Bioreagents | 500 ul | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955PE-100T | NSJ Bioreagents | 100 Tests | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |